Mizutomo Azuma

FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

Wu Zhang, Michael A. Gordon, Anne M. Schultheis et al. · Journal of Clinical Oncology · 2007 · 480 citations

Medicine, Oncology, Pharmacology +16

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Narikazu Boku, Min‐Hee Ryu, Ken Kato et al. · Annals of Oncology · 2018 · 320 citations · Full text

Medicine, Oncology, Pharmacology +14

High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and bFGF

Andreas-Claudius Hoffmann, Daniel Vallböhmer, Jan Brabender et al. · Neoplasia · 2008 · 145 citations · Full text

Medicine, Oncology, Pathology +13

Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center

Satoshi Tanabe, Kenji Ishido, Katsuhiko Higuchi et al. · Gastric Cancer · 2013 · 127 citations · Full text

Medicine, Oncology, Surgery +14

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

Yasuhide Yamada, Narikazu Boku, Junki Mizusawa et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 125 citations

Medicine, Oncology, Pharmacotherapy +7